Henlius carves out $440M T-cell engager deal with Amberstone
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million deal with California-based Amberstone Biosciences to work on T-cell engagers.
Henlius Biopharmaceuticals
Private
Shanghai Henlius Biotech is a Chinese biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality biosimilars and innovative oncology biologics, with a portfolio marketed in China, Europe, and emerging markets.
Company Info
Sector:Biosimilars / Oncology biologics
Headquarters:Shanghai, China
Founded:2009
Website:www.henlius.com/en/index.html